Effect of alpha-lipoic acid and vitamin E supplementation on oxidative stress, inflammation, and malnutrition in hemodialysis patients.
BACKGROUND
Increased oxidative stress, inflammation, and malnutrition are present in hemodialysis patients and these factors exacerbate cardiovascular comorbidities. Vitamin E and alpha-lipoic acid (ALA) may have a protective role against cardiovascular disease risk factors via anti-oxidative and anti-inflammatory properties. The aim of this study was to evaluate the effect of ALA and vitamin E administration (alone or combined) on hemodialysis-induced stress oxidation, inflammation, and malnutrition.


METHODS
In a randomized placebo-controlled trial, we examined the effects of 2-month supplementation by vitamin E and ALA (alone or combined) on biomarkers of lipid peroxidation (malondialdehyde), inflammation (high-sensitivity C-Reactive protein and interleukin-6), and malnutrition (Subjective Global Assessment and body mass index) in 85 hemodialysis patients receiving ALA (600 mg), vitamin E (400 IU), ALA and vitamin E, and placebo.


RESULTS
After supplementation, no significant changes were observed in malondialdehyde level; however, there was a decrease in the ALA and vitamin E group during the period of the study. Also, a nonsignificant decrease was seen in the high-sensitivity C-Reactive protein concentration of the interventional groups. Supplementation of vitamin E with and without ALA significantly reduced interleukin-6 concentration. A significant improvement was observed in malnutrition status of all groups.


CONCLUSIONS
Vitamin E and ALA supplementation, especially their combination, might improve inflammation and malnutrition status, which suggest it as a potential preventive strategy against CVD among end-stage renal disease patients.
Department of Nutrition, School of Health and Nutrition, Shiraz University of Medical Sciences, Shiraz, Iran. ahmadi.afsane@yahoo.com.
Afsane
A
Ahmadi
Negin
N
Mazooji
Jamshid
J
Roozbeh
Zohre
Z
Mazloom
Jafar
J
Hasanzade
D000328:Adult; D000975:Antioxidants / Q000008:administration & dosage*; D002097:C-Reactive Protein / Q000187:drug effects / Q000378:metabolism; D019587:Dietary Supplements; D005260:Female; D006801:Humans; D007249:Inflammation / Q000097:blood / Q000188:drug therapy*; D015850:Interleukin-6 / Q000097:blood; D008297:Male; D044342:Malnutrition / Q000097:blood / Q000188:drug therapy*; D008315:Malondialdehyde / Q000097:blood; D008875:Middle Aged; D018384:Oxidative Stress / Q000187:drug effects*; D006435:Renal Dialysis / Q000009:adverse effects; D008063:Thioctic Acid / Q000008:administration & dosage*; D016896:Treatment Outcome; D014810:Vitamin E / Q000008:administration & dosage*
D000975:Antioxidants; D015850:Interleukin-6; D014810:Vitamin E; D008315:Malondialdehyde; D008063:Thioctic Acid; D002097:C-Reactive Protein